Pharmacologic vitreolysis with plasmin and hyaluronidase in diabetic rats

Retina

Volumn 29, Issue 2, 2009, Pages 269-274

  Zhi Liang, Wang ^a   Wo Dong, Shi ^a   Min, Luo ^a   Xiao Ping, Bi ^a   Jin, Ji ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BALANCED SALT SOLUTION; HYALURONIDASE; PLASMIN; FIBRINOLYTIC AGENT; HYALURONOGLUCOSAMINIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMOPROPHYLAXIS; CLINICAL OBSERVATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIABETIC RETINOPATHY; ELECTRORETINOGRAPHY; FEASIBILITY STUDY; MONOTHERAPY; NONHUMAN; RANDOMIZATION; RAT; RETINA EDEMA; RETINA EXUDATE; RETINA HEMORRHAGE; SCANNING ELECTRON MICROSCOPY; STREPTOZOCIN DIABETES; TRANSMISSION ELECTRON MICROSCOPY; VITREOUS BODY DETACHMENT; ANIMAL; BASEMENT MEMBRANE; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; DRUG EFFECT; EXPERIMENTAL DIABETES MELLITUS; INJECTION; PHYSIOLOGY; RETINA; SPRAGUE DAWLEY RAT; ULTRASTRUCTURE; VITREOUS BODY;

ANIMALS; BASEMENT MEMBRANE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; DRUG THERAPY, COMBINATION; ELECTRORETINOGRAPHY; FIBRINOLYTIC AGENTS; HYALURONOGLUCOSAMINIDASE; INJECTIONS; MICROSCOPY, ELECTRON, SCANNING; PLASMIN; RATS; RATS, SPRAGUE-DAWLEY; RETINA; VITREOUS BODY; VITREOUS DETACHMENT;

EID: 63249123345     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181923ff0     Document Type: Article

References (26)

1. Gardiner TA, Anderson HR, Stitt AW. Inhibition of advanced glycation end-products protects against retinal capillary basement membrane expansion during long-term diabetes. J Pathol 2003;201:328 -333.
2. The PKC-DRS Study Group. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial. Diabetes 2005;54:2188 -2197.
3. Mason JO III, Nixon PA, White MF. Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 2006;142:685-688.
4. Kakehashi A, Kado M, Akiba J, Hirokawa H. Variations of posterior vitreous detachment. Br J Ophthalmol 1997;81:527-532.
5. Ono R, Kakehashi A, Yamagami H, et al. Prospective assessment of proliferative diabetic retinopathy with observations of posterior vitreous detachment. Int Ophthalmol 2005;26:15-19.
6. Akiba J, Arzabe CW, Trempe CL. Posterior vitreous detachment and neovascularization in diabetic retinopathy. Ophthalmology 1990;97:889-891.
7. Mazurina NK. The current data on the proliferative process in diabetic retinopathy. Vestn Ofalmol 1999;115:37- 40.
8. Sebag J. Pharmacologic vitreolysis. Retina 1998;18:1-3.
9. Gandorfer A. Enzymatic vitreous disruption. Eye 2008;22: 1273-1277.
10. Sebag J. Pharmacologic vitreolysis brewing? Retina 2002;22: 1-3.
11. Li W, Shen S, Khatami M. Stimulation of retinal capillary pericyte protein and collagen synthesis in culture by high-glucose concentration. Diabetes 1984;33:785-789.
12. Hancock HA, Kraft TW. Oscillatory potential analysis and ERGs of normal and diabetic rats. Invest Ophthalmol Vis Sci 2004;45:1002-1008.
13. Verstraeten TC, Chapman C, Hartzer M, Winkler BS, Trese MT, Williams GA. Pharmacologic induction of posterior vitreous detachment in the rabbit. Arch Ophthalmol 1993;111: 849-854.
14. Wang ZL, Zhang X, Xu X, Sun XD, Wang F. PVD following plasmin but not hyaluronidase: implications for combination pharmacologic vitreolysis therapy. Retina 2005;25:38-43.
15. Akiba J, Ueno N, Chakrabarti B. Molecular mechanisms of posterior vitreous detachment. Graefes Arch Clin Exp Ophthalmol 1993;231:408-412.
16. Sebag J, Balazs EA. Morphology and ultrastructure of human vitreous fibers. Invest Ophthalmol Vis Sci 1989;30:1867-1871.
17. Li X, Shi X, Fan J. Posterior vitreous detachment with plasmin in the isolated human eye. Graefes Arch Clin Exp Ophthalmol 2002;240:56-62.
18. Liotta LA, Goldfard RH, Brundage R, et al. Effect of plasmin-ogen activator, plasmin, and collagenous components of basement membrane. Cancer Res 1981;41:4629-4636.
19. Sebag J, Ansari RR, Suh KI. Pharmacologic vitreolysis with microplasmin increases vitreous diffusion coefficients. Graefes Arch Clin Exp Ophthalmol 2007;245:576-580.
20. Sebag J, Buckingham B, Charles MA, et al. Biochemical abnormalities in vitreous of humans with proliferative diabetic retinopathy. Arch Ophthalmol 1992;110:1472-1476.
21. Sebag J, Nie S, Reiser K, Charles MA, Yu NT. Raman spec-troscopy of human vitreous in proliferative diabetic retinopa-thy. Invest Ophthalmol Vis Sci 1994;35:2976-2980.
22. Sebag J. Abnormalities of human vitreous structure in diabetes. Graefes Arch Clin Exp Ophthalmol 1993;231:257-260.
23. Sebag J, Ansari RR, Dunker S, Suh KI. Dynamic light scattering of diabetic vitreopathy. Diabetes Technol Ther 1999;1: 169-176.
24. Sebag J. Diabetic vitreopathy. Ophthalmology 1996;103:205-206.
25. Hikichi T, Kado M, Yoshida A. Intravitreal injection of hyaluronidase cannot induce posterior vitreous detachment in the rabbit. Retina 2000;20:195-198.
26. Sebag J. Anomalous posterior vitreous detachment: a unifying concept in vitreo-retinal disease. Graefes Arch Clin Exp Ophthalmol 2004;242:690-698.